In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. Royalty Pharma plc is one of them.
Royalty Pharma plc (NASDAQ:RPRX) tops our list for being one of the best performing stocks. It is a leading biopharmaceutical royalty company that invests in innovative drug products, partnering with biotech firms, pharmaceutical companies, and research institutions to fund late-stage clinical trials and new product launches in exchange for future royalty earnings.
In Q2 2025, Royalty Pharma plc (NASDAQ:RPRX) reported strong growth, with Portfolio Receipts rising 20% to $727 million and Royalty Receipts up 11%, driven by products including Trelegy, Evrysdi, and Tremfya. Reflecting confidence in its portfolio, the business updated its full-year 2025 guidance for Portfolio Receipts to $3.05–$3.15 billion, projecting 9%–12% growth.
A key milestone was the acquisition of its external management firm, RP Management, LLC, in May 2025. This internalization streamlined operations and integrated the royalty portfolio with the company’s intellectual property assets, enhancing efficiency and strategic flexibility.
The firm has also expanded its oncology presence, acquiring a royalty interest in Amgen’s Imdelltra, a novel bispecific-cell engager for small cell lung cancer, for an upfront $885 million with potential royalties up to $65 million. Further portfolio diversification came through a $2 billion funding arrangement with Revolution Medicines, including $1.25 billion to purchase a synthetic royalty on daraxonasib and a secured senior loan of $750 million.
Additionally, in September 2025, Royalty Pharma plc (NASDAQ:RPRX) announced up to $300 million in funding for Zenas Biopharma’s obexelimab in exchange for royalties, underscoring its commitment to supporting innovative pipeline products.
While we acknowledge the potential of RPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure. None.